Auto Stem Cell Transplant for Lymphoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

September 30, 2025

Study Completion Date

April 30, 2026

Conditions
Non-Hodgkin LymphomaHodgkin Lymphoma
Interventions
DRUG

Etoposide

"BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \

DRUG

BCNU

BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6

DRUG

AraC

BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2

DRUG

Melphalan

BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1

PROCEDURE

Peripheral blood stem cell transplantation

All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.

BIOLOGICAL

G-CSF

All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3

DRUG

Cyclophosphamide

"CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \

RADIATION

Total Body Irradiation

CY/TBI: 165 cGy bid on Day -4, -3, -2, -1

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER